Anti-corruption campaigns in China, a shift towards leasing systems and the ever-problematic presence of GLP-1 inhibitors has led analysts, journalists and commentators to voice concerns about the robotic surgery giant.
Against a variety of headwinds, Intuitive Surgical placed 322 new da Vinci systems worldwide in the third quarter and saw its procedure volume grow 19% compared to the third quarter of 2022, building on momentum from the first half of 2023.
“We saw strong growth in procedures performed by our customers, solid new system placements and healthy growth and utilization amid...
Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.
Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.
Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.
An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.
Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.
